BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

713 related articles for article (PubMed ID: 8784011)

  • 1. Molecular markers help characterize neuroendocrine lung tumors.
    Rusch VW; Klimstra DS; Venkatraman ES
    Ann Thorac Surg; 1996 Sep; 62(3):798-809; discussion 809-10. PubMed ID: 8784011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
    Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
    Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival.
    Skov BG; Holm B; Erreboe A; Skov T; Mellemgaard A
    J Thorac Oncol; 2010 Apr; 5(4):453-9. PubMed ID: 20104194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pulmonary neuroendocrine tumors in the new WHO 2015 classification: Start of breaking new grounds?].
    Schnabel PA; Junker K
    Pathologe; 2015 May; 36(3):283-92. PubMed ID: 25956813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid.
    Travis WD; Rush W; Flieder DB; Falk R; Fleming MV; Gal AA; Koss MN
    Am J Surg Pathol; 1998 Aug; 22(8):934-44. PubMed ID: 9706973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular markers for reinforcement of histological subclassification of neuroendocrine lung tumors.
    Kobayashi Y; Tokuchi Y; Hashimoto T; Hayashi M; Nishimura H; Ishikawa Y; Nakagawa K; Sato Y; Takahashi A; Tsuchiya E
    Cancer Sci; 2004 Apr; 95(4):334-41. PubMed ID: 15072592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour suppressor gene products, proliferation, and differentiation markers in lung neuroendocrine neoplasms.
    Barbareschi M; Girlando S; Mauri FA; Arrigoni G; Laurino L; Dalla Palma P; Doglioni C
    J Pathol; 1992 Apr; 166(4):343-50. PubMed ID: 1355531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. hASH1 is a specific immunohistochemical marker for lung neuroendocrine tumors.
    Ye B; Cappel J; Findeis-Hosey J; McMahon L; Yang Q; Xiao GQ; Xu H; Li F
    Hum Pathol; 2016 Feb; 48():142-7. PubMed ID: 26596584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Automated quantification of Ki-67 proliferative index of excised neuroendocrine tumors of the lung.
    Liu SZ; Staats PN; Goicochea L; Alexiev BA; Shah N; Dixon R; Burke AP
    Diagn Pathol; 2014 Oct; 9():174. PubMed ID: 25318848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bcl-2, p53, CD44, and CD44v6 isoform expression in neuroendocrine tumors of the lung.
    Coppola D; Clarke M; Landreneau R; Weyant RJ; Cooper D; Yousem SA
    Mod Pathol; 1996 May; 9(5):484-90. PubMed ID: 8733762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential retinoblastoma and p16(INK4A) protein expression in neuroendocrine tumors of the lung.
    Dosaka-Akita H; Cagle PT; Hiroumi H; Fujita M; Yamashita M; Sharma A; Kawakami Y; Benedict WF
    Cancer; 2000 Feb; 88(3):550-6. PubMed ID: 10649246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors.
    Brambilla E; Negoescu A; Gazzeri S; Lantuejoul S; Moro D; Brambilla C; Coll JL
    Am J Pathol; 1996 Dec; 149(6):1941-52. PubMed ID: 8952529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in neuroendocrine lung tumors.
    Travis WD
    Ann Oncol; 2010 Oct; 21 Suppl 7():vii65-71. PubMed ID: 20943645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroendocrine tumors of the lung: A five-year retrospective experience of Egyptian NCI (2010-2014).
    Saber M; Ismail Y; Alieldin N; Loay I; El Zawahry M
    J Egypt Natl Canc Inst; 2018 Dec; 30(4):151-158. PubMed ID: 30470605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary neuroendocrine tumors: study of 90 cases focusing on clinicopathological characteristics, immunophenotype, preoperative biopsy, and frozen section diagnoses.
    Yeh YC; Chou TY
    J Surg Oncol; 2014 Mar; 109(3):280-6. PubMed ID: 24301337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Large cell neuroendocrine carcinoma of the lung: a histologic and immunohistochemical study of 22 cases.
    Jiang SX; Kameya T; Shoji M; Dobashi Y; Shinada J; Yoshimura H
    Am J Surg Pathol; 1998 May; 22(5):526-37. PubMed ID: 9591721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative evaluation of three proliferation markers, Ki-67, TOP2A, and RacGAP1, in bronchopulmonary neuroendocrine neoplasms: Issues and prospects.
    Neubauer E; Wirtz RM; Kaemmerer D; Athelogou M; Schmidt L; Sänger J; Lupp A
    Oncotarget; 2016 Jul; 7(27):41959-41973. PubMed ID: 27259241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential retinoblastoma protein expression in neuroendocrine tumors of the lung. Potential diagnostic implications.
    Cagle PT; el-Naggar AK; Xu HJ; Hu SX; Benedict WF
    Am J Pathol; 1997 Feb; 150(2):393-400. PubMed ID: 9033254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pulmonary neuroendocrine tumors and preneoplasic lesions].
    Rouquette Lassalle I
    Ann Pathol; 2016 Jan; 36(1):34-43. PubMed ID: 26776366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of thyroid transcription factor-1 in the spectrum of neuroendocrine cell lung proliferations with special interest in carcinoids.
    Sturm N; Rossi G; Lantuejoul S; Papotti M; Frachon S; Claraz C; Brichon PY; Brambilla C; Brambilla E
    Hum Pathol; 2002 Feb; 33(2):175-82. PubMed ID: 11957142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.